Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | excitatory amino acid transporter 2 | 0.0366 | 0.9274 | 0.9274 |
Treponema pallidum | glutamate transporter | 0.0162 | 0 | 0.5 |
Chlamydia trachomatis | glutamate symporter | 0.0366 | 0.9274 | 1 |
Echinococcus multilocularis | neutral amino acid transporter A | 0.0366 | 0.9274 | 0.9274 |
Echinococcus multilocularis | Excitatory amino acid transporter | 0.0366 | 0.9274 | 0.9274 |
Echinococcus multilocularis | sodium:dicarboxylate symporter | 0.0366 | 0.9274 | 0.9274 |
Echinococcus multilocularis | neutral amino acid transporter A | 0.0366 | 0.9274 | 0.9274 |
Schistosoma mansoni | solute carrier family 1 (glial high affinity glutamate transporter | 0.0366 | 0.9274 | 1 |
Echinococcus multilocularis | neutral amino acid transporter A | 0.0366 | 0.9274 | 0.9274 |
Brugia malayi | Excitatory amino acid transporter | 0.0366 | 0.9274 | 0.5 |
Mycobacterium tuberculosis | Probable C4-dicarboxylate-transport transmembrane protein DctA | 0.0366 | 0.9274 | 0.5 |
Echinococcus multilocularis | excitatory amino acid transporter 3 | 0.0366 | 0.9274 | 0.9274 |
Loa Loa (eye worm) | hypothetical protein | 0.0374 | 0.9641 | 1 |
Treponema pallidum | glutamate/aspartate transporter | 0.0162 | 0 | 0.5 |
Echinococcus multilocularis | neutral amino acid transporter excitatory amino acid transporter | 0.0366 | 0.9274 | 0.9274 |
Echinococcus multilocularis | excitatory amino acid transporter 2 | 0.0366 | 0.9274 | 0.9274 |
Echinococcus multilocularis | Excitatory amino acid transporter | 0.0366 | 0.9274 | 0.9274 |
Wolbachia endosymbiont of Brugia malayi | Na+/H+-dicarboxylate symporter | 0.0366 | 0.9274 | 0.5 |
Onchocerca volvulus | Excitatory amino acid transporter homolog | 0.0366 | 0.9274 | 0.5 |
Echinococcus multilocularis | smoothened | 0.0382 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Decrease in QA interval (functional) | ND 0 | Compound was administered orally to conscious adult beagle dogs (n=4) and the effects on cardiac contractility was determined after 1 hr; ND means no data. | ChEMBL. | 2544726 |
Decrease in QA interval (functional) | ND 0 | Compound was administered orally to conscious adult beagle dogs (n=4) and the effects on cardiac contractility was determined after 3 hr; ND means no data. | ChEMBL. | 2544726 |
Increase in dP/dTmax (functional) | = 24 % | Positive inotropic activity after intravenous administration of 50 ug/kg (dose) to anesthetized dog | ChEMBL. | 2544726 |
Relative inotropic potency (functional) | = 0.6 | Inotropic potencies relative to 4-[4-[2-(1,1-dioxo-2-isothiazolidinyl)ethyl]-1-piperidinyl]-6,7-dimethoxyquinazoline (50 ug/kg) in anesthetized dog | ChEMBL. | 2544726 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.